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Abstract
Purpose Assessment of tumor proliferation rate using Bromodeoxyuridine labeling index (BrdUrdLI) as a possible
predictor of rectal cancer response to preoperative radiotherapy (RT).
Methods and material Ninety-two patients were qualified either to short RT (5 Gy/fraction/5 days) and surgery about
1 week after RT (schedule I), or to short RT and 4–5 weeks interval before surgery (schedule II). Tumor samples were taken
twice from each patient: before RTand at the time of surgery. The samples were incubated with BrdUrd for 1 h at 37°C, and
the BrdUrdLI was calculated as a percentage of BrdUrd-labeled cells.
Results Thirty-eight patients were treated according to schedule I and 54 patients according to schedule II. Mean BrdUrdLI
before RT was 8.5% and its value did not differ between the patients in the two compared groups. After RT tumors showed
statistically significant growth inhibition (reduction of BrdUrdLI). As the pretreatment BrdUrd LI was not predictive for
early clinical and pathologic tumor response, prognostic role of the ratio of BrdUrdLI after to BrdUrdLI before RT was
considered. The ratios were calculated separately for fast (BrdUrd LI>8.5%) and slowly (BrdUrd LI≤8.5%) proliferating
tumors and correlated with overall treatment time (OTT, i.e., time from the first day of RT to surgery). One month after RT,
accelerated proliferation was observed only in slowly proliferating tumors.
Conclusions Pretreatment BrdUrdLI was not predictive for early clinical and pathologic tumor response. The ratio after/
before RT BrdUrdLI was correlated to inhibition of proliferation in responsive tumors.
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In specialized centers, a refined surgical technique has
resulted in high local control figures in rectal cancer.
However, local recurrence rates after “standard” surgery are
generally high, with figures ranging between 20 and 40%
1,2,
although after adopting the total mesorectal excision (TME)
concept they fell down to 10–12%
3,4. Radiotherapy in
addition to surgery significantly diminishes the risk of local
failure by more than half, from 8 to 2% after 2 years
3.
Therefore, combined treatment: radiotherapy (RT) and
surgery in the treatment of patients with resectable rectal
cancer has been proposed in many trials using either
preoperative
5,6 or postoperative irradiation
7,8. Better results
of preoperative RT for 5 days (25 Gy in five fractions) in
comparison with postoperative 60 Gy in 30 fractions were
achieved by a Swedish group
4,9,10, with respect to the local
recurrence rate
11 and overall survival
11,12.
A corresponding improvement in overall survival has not
been demonstrated after postoperative radiotherapy alone
13.
Graf’s
12 study provided a clinically significant biologic
effect of a short preoperative course of radiotherapy on the
tumor size and on the incidence of nodal metastases;
however, this effect was minimized if surgery was
performed immediately after radiotherapy. The effect is
most likely caused by death of tumor cells in the primary
tumor and in the involved nodes. A short treatment course
of radiotherapy, i.e., 5×5 Gy is desirable, and this regimen
is currently considered as the gold standard in many
centers. However, using this schedule it is difficult to
observe a down-staging and/or downsizing of the tumor,
which is of importance for the selection of patients for
sphincter-preserving surgery (anterior resection).
In clinical practice there are no certain methods able to
predict tumor response to preoperative radiotherapy (RT).
The optimal timing of surgery after preoperative radiother-
apy in rectal cancer is unknown. However, it was shown
that a long interval (6–8 weeks) between preoperative
radiotherapy (39 Gy in 13 fractions) and surgery was
associated with a significantly greater clinical tumor
volume reduction than a short interval (2 weeks)
14.O n
the other hand, it was shown that subclinical pelvic deposits
of rectal cancer could grow rapidly during preoperative
radiation therapy and during the radiotherapy–surgery
interval, with an adverse influence on the rate of pelvic
tumor control from protracting the overall treatment time
15.
Graf et al
12 showed that low doses in short RT only offer
clinically relevant reduction in the risk of pelvic relapses if
the overall radiation treatment time is short. Thus, the rate
of cancer cell proliferation seems to be a very important
prognostic factor.
The aim of this study is to evaluate BrdUrd LI and S-
phase fraction (SPF) as the possible indicators of tumor
proliferation rate and predictors of the tumor response to
neoadjuvant RTin patients with rectal cancer, and to suggest
an optimal interval between short RT course and surgery.
Methods and Materials
Patients
Between November 2003 and January 2006 we recruited 92
patients with resectable rectal carcinoma for whom curative
surgery was planned. Patients were eligible for the trial if
they were less than 75 years old, had a histopathologically
proved adenocarcinoma (T2/T3)
16 situated less than 12 cm
from the verge of the anus, and gave informed consent for
their participation. The protocol was approved by the
Ethical Committee of the Center of Oncology, and each
patient gave written consent.
The criteria for exclusion were: locally nonresectable
tumor; plan to perform only local tumor excision; known
metastatic disease; previous radiotherapy of pelvis region;
other malignant disease; and patient’s refusal.
Preoperative Radiotherapy
The patients assigned to preoperative radiotherapy received
a total tumor dose of 25 Gy. The treatment was given in
five fractions over 5 days, one posterior and two lateral
wedged fields were irradiated with photons of maximum
6 MV energy. According to the random selection surgery
was performed the following week (schedule I) or after
longer interval of 4–5 weeks (schedule II).
Surgery
Anterior resection of rectum or abdominoperineal excision
was performed within a week or a month after the
completion of RT. Type of surgery was resection of the
rectum and lower sigmoid with involved adjacent tissue and
regional lymph nodes up to or above the origin of inferior
mesenteric artery. A minimal touch technique was used
with high tight ligation of the inferior mesenteric artery.
The decision whether the patient should have an abdomi-
noperineal resection or a sphincter-preserving surgery was
made by the surgeon during the operation.
An abdominoperineal resection of rectum was performed
in 41 (44.6%) of the patients, and sphincter preserving
surgery was performed in 51 (55.4%).
Biological Assessment of Tumor Response
Tumor samples were taken twice: before radiotherapy
(through a rectoscope) and during surgery from the same
J Gastrointest Surg (2007) 11:520–528 521place, i.e., at the lowest edge of the tumor mass. Each
biopsy was divided into two parts: one was used for
BrdUrd LI assessment, and the second was used for
immunohistochemical analysis (these results will be the
subject of a separate study).
Bromodeoxyuridine Labeling Index
Incorporation of BrdUrd in tumor samples from a biopsy
(0.3–0.5 cm
3) was carried out in vitro according to the high-
pressure oxygen method. The BrdUrd staining procedure
and flow cytometry have been described in detail else-
where
17. The stained preparations were analyzed with a
FACS Calibur flow cytometer (Becton Dickinson Immuno-
cytometry Systems, Sunnyvale, CA, USA) by one coauthor
(AG) and 20×10
3 events were collected in each histogram.
The BrdUrdLI was calculated as a percentage of BrdUrd-
labeled cells in a sample, which incorporated BrdUrd during
1 h of incubation at 37°C (with discrimination of diploid
subpopulation in aneuploid tumors). The tumor ploidy and
SPF were calculated from the DNA profile with ModFit
software running on a MacIntosh computer. Apoptotic cells
were identified as objects with a fractional DNA content not
less than 20% of the 2n DNA content. Cell death was
calculated as the sum of apoptosis and debris. The tumor
ploidy was estimated by evaluating the DNA index, i.e., the
ratio of the modal DNA fluorescence of abnormal to normal
G1/0 cells. Aneuploidy was assessed in cases in which the
normal and neoplastic cell populations gave two separate
peaks. Human lymphocytes were used for the reference
peak. Tumors with BrdUrdLI >8.5% (median value) were
considered as fast, and those with BrdUrdLI ≤8.5% were
considered as slowly proliferating tumors.
Clinical Assessment of Tumor Response
Tumor size before RT was assessed basing on measures
taken during rectoscopy, and endorectal sonography. Tumor
regression after RT was assessed at the time of operation by
surgeons according to the following Response Evaluation
Criteria in Solid Tumors (RECIST)
18:
Complete response (CR): 100% disappearance; partial
response (PR): 30–99% decrease; stable disease (SD):
neither CR, PR or PD criteria met; progression of disease
(PD): 20% increase in sums of tumor longest diameters.
Pathological Assessment of Tumor Response
Tumor regression after RT was evaluated by a pathologist
on the excised tumor mass. The following criteria of tumor
regression assessed by Dworak et al.
19 were applied:
D0—no regression; D1—dominant tumor mass with
obvious fibrosis and/or vasculopathy; D2—dominantly
fibrotic changes with few tumor cells or groups; D3—very
few (difficult to find microscopically) tumor cells in fibrotic
tissue with or without mucous substance; D4—no tumor
cells, only fibrotic mass (total regression or response).
Statistical Methods
Statistical analysis was performed with STATISTICA vs.5.
Intergroup differences in the ordinal data were tested with
ANOVA test or Student’s t test. P values of less than 0.05
were considered to indicate statistical significance. Linear
regression was applied for assessing differences between
fast and slowly proliferating tumors in relation with OTT,
and its significance was determined by testing the differ-
ence between two correlation coefficients. Stratification by
BrdUrd LI level was introduced and tested by the inclusion
of dummy variable in the regression model.
Results
Patients
A total of 92 patients were included in the study. Twenty-
eight (23.3%) out of 120 patients initially qualified for this
study were excluded from the analysis because of discon-
tinuation of treatment, metastatic tumor noticed at opera-
tion, or no tumor samples taken for biological assessment
during surgery. Mean age for the entire group of patients
was 61.6 years (range 30–75). There were 68 men and 24
women. There were no statistical differences between the
two groups at the time of recruitment for prognostic factors
such as: sex, age, histologic grade, or tumor stage (Table 1).
In our series of patients, there were 27 stage 1 (29.3%),
55 were T2 (59.8%), and 10 were T3 (10.9%). In 26
patients, tumor cells well differentiated (G1), 63 moderately
differentiated (G2), and three poorly differentiated (G3)
(Table 1). Thirty-eight patients were treated according to
schedule I, in which time interval between end of
irradiation and surgery averaged 8.8 days (range 2–14;
Table 1). In 54 patients, schedule II was applied, in which
mean break was 32.9 days (range 17–45). Because the
interval between RT and surgery appeared to be longer than
planned, overall treatment time (OTT), e.g., time from the
beginning of RT to surgery, was calculated and it appeared
to be 7–50 days (Table 1).
Biologic, Pathologic, and Clinical Assessment
of Tumor Response
Mean BrdUrd LI before RT was 8.5% (range 1.0–24.2%)
and SPF was 22.0% (range 3.8–49.9%) and the mean
values did not differ between the two schedules (Table 2).
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higher BrdUrd LI than grades 1 and 2 tumors (P=0.015;
Table 3). After RT, tumors treated according to both
schedules showed statistically significant growth inhibition
(reduction of BrdUrd LI and percentage of SPF cells) in
comparison with the values obtained before RT (Table 2).
Radiation induced inhibition of tumor proliferation was
expressed as a percentage of the after RT to before RT
BrdUrd LI, and SPF as after/before RT percentage. This
ratio ranged from 2.5 to 514% for BrdUrd LI (Fig. 1) and
from 5.8 to 522.2% for SPF. When we stratified patients
into two groups according to their biological RT response,
those radioresponsive with reduction of pretreatment values
after radiotherapy above 50% and those less responsive
with reduction below 50%, it appeared that the mean values
(of the after/before RT ratios of BrdUrd LI and SPF) for the
more radioresponsive tumors were significantly higher than
for the less responsive ones. Therefore, these ratios were
presented separately for fast (BrdUrd LI >8.5%, SPF
>22.0%) and slowly (BrdUrd LI ≤8.5%, SPF ≤22.0%)
proliferating tumors. Mean BrdUrd LI value after RT for
fast proliferating tumors (41 cases) showed statistically
significant (P=0.027) reduced pretreatment percentage
(46.8%) in comparison with slowly proliferating tumors
(85.3%, 51 cases). The same was true for SPF of fast
(56.4%, 55 cases) and slowly (113.8%, 37) proliferating
tumors (P=0.006).
Next, the after/before RT ratios for BrdUrd LI and SPF
were correlated with OTT. For SPF, statistical difference
between linear regression coefficients for fast and slowly
proliferating tumors was not obtained (P=0.446), therefore
the data for BrdUrd LI only are shown (Fig. 1). Insert on
Fig. 1 shows a significant (P=0.033) difference in
proliferation rate between fast and slowly proliferating
tumors treated within OTT >30 days. At that time slowly
proliferating tumors, contrary to fast proliferating ones,
show no inhibition but accelerated proliferation of tumor
cells. This phenomenon was also confirmed by increased
fraction of S-phase cells in tumors treated with longer RT
schedule (Table 2). The influence of BrdUrdLI level has
been also tested by the extended regression model between
OTT and the percentage of after/before RT BrdUrd LI.
BrdUrd LI level higher than 8.5% has been coded as
dummy variable. It appeared to be significant (P=0.025) in
the relation between OTT and the percentage of after/before
RT BrdUrd LI. The partial regression coefficient indicates
that the average decrease of the percentage after/before RT
BrdUrdLI for fast proliferating tumors (BrdUrd LI >8.5%)
equals 39%.
All 92 irradiated rectal tumors were reviewed by the
same pathologist (KN). The tumors were classified accord-
ing to the World Health Organization classification of
Table 2 Status of Biological Parameters Before and After RT
Group BrdUrd LI
(%) Mean
(range)
S-phase fraction
(%) Mean
(range)
Apoptosis
(%) Mean
(range)
All patients
Before
RT
8.5 (1.0–24.2) 22.0 (3.8–49.9) 5.9 (0–52.8)
After
RT
4.1* (0.4–18.3) 16.8** (1.5–101.0) 9.8*** (0–45.9)
RT schedule I
Before
RT
8.4 (1.1–24.2) 21.5 (6.1–49.2) 6.6 (0–32.4)
After
RT
3.8*(0.8–12.6) 14.1****
(1.5–47.9)
10.5 (0–43.3)
RT schedule II
Before
RT
8.6 (1.0–20.0) 22.3 (3.8–49.9) 5.4 (0–52.8)
After
RT
4.5* (0.4–18.3) 17.2 (2.6–101.0) 9.5*****
(0–45.9)
*P=0.000
**P=0.015
***P=0.010
****P=0.002
Table 1 Selected Characteristics of Patients and Treatment Parameters
Characteristics Schedule I Schedule II Total
Age mean (±SD)
years
(38)
a 61.2±
12.0
(54) 61.9±
9.5
(92) 61.6±
10.6
Sex
Male 30 38 68
Female 8 16 24
Histological grade
G1 6 20 26
G2 29 34 63
G3 3 0 3
Tumor stage
T1 8 19 27
T2 25 30 55
T3 5 5 10
PTNM
11 6 2 5 4 1
28 6 1 4
31 3 1 7 3 0
41 2 3
Interval between RT and surgery
Mean (range) days (38)
a 8.8
(2–14)
(54) 32.9
(17–45)
(92) 22.9
(2–45)
OTT mean
(range) days
(38) 13.8
(7–19)
(54) 37.9
(22–50)
(92) 27.9
(7–50)
Surgery
Sphincter-preserving 20 (52.6 %) 31(57.4 %) 51
Abdominoperineal
resection
18 23 41
aNumber of patients
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16 and staged according to the TNM
classification
20. Of the 92 rectal tumors four had no pTNM
classification, 41 were pT1 (46.6%), 14 were pT2 (15.9%),
30 were pT3 (34.1%), and three were pT4 (3.4%). Regional
lymph node metastases were found in 27 (30.7%) patients,
and 27 (30.7%) patients had their tumor down-staged.
Pathologic assessment of tumor regression after RT
according to classification described by Dworak
19 was
performed in 90 out of 92 patients (for two patients the
assessment was impossible). The analysis showed no tumor
regression (D0) in 18 (20.0%) tumors, dominant tumor
mass (D1) in 46 (51.1%) tumors, a few tumor cells in
fibrotic mass (D2) in 18 (20.0%) tumors, single tumor cells
(D3) in four (4.4%), and no tumor cells were observed in
four (4.4%) of the examined tumors (Fig. 2a). In 25
(27.8%) out of 90 patients marked pathologic down-staging
(no residual tumor confined to the rectal wall) was visible.
Pretreatment BrdUrdLI and SPF were not correlated with
early clinical and pathologic tumor response. However,
patients having tumors with LI >8.5% were more radio-
responsive (showed significant reduction in proliferative
rate after radiotherapy) than patients with BrdUrdLI ≤8.5%
tumors, although statistically significant difference between
the two tumor subgroups was seen only for D0–D1 grade
(Fig. 2b).
In the clinical assessment of tumor mass resected during
surgery, 34 (36.9%) tumors showed stable disease, 12
(13.0%) showed progressive disease, 41 (44.6%) showed
partial response, and four (4.3%) showed complete
response (Fig. 3a). And again, in fast proliferating tumors,
greater inhibition in tumor proliferation rate (reduction of
pretreatment BrdUrd LI value >50%) was observed in fast
than in slowly proliferating tumors; however, this differ-
ence was not statistically significant (Fig. 3b). As the
observed correlation between clinical assessment and SPF
was weaker than for BrdUrd LI, the data were not shown.
Partial and total tumor regression was observed in 45
(48.9%) tumors. However, tumor proliferation status was
not in agreement with the kind of surgery. Sphincter-
preserving surgery was performed in 51 out of 92 patients: in
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Figure 1 The association
between biological tumor
response for slowly (BrdUrd
LI≤8.5%; closed symbol) and
faster proliferating tumors
(BrdUrd LI>8.5%; open
symbol) and overall treatment
time. Insert shows linear regres-
sion performed separately for
each of the tumor subgroups for
OTT>30 days. P value shows
difference between two
correlation coefficients.
Table 3 The Relationship Between Tumor Biological Parameters and Histological Grade
Histological grade N BrdUrd LI (%) Mean (range) S-phase fraction (%) Mean (range) Apoptosis (%) Mean (range)
G1 26 8.5 (1.1–17.1) 23.7 (5.8–49.9) 3.4 (0–32.4)
G2 61 8.2 (1.0–20.0) 21.0 (3.8–45.6) 7.2 (0–52.8)
G3 3 16.2*, ** (9.5–24.2) 27.7 (18.9–34.7) 2.1 (0.4–4.8)
*P=0.015, difference between G1 and G3
**P=0.013, difference between G2 and G3
524 J Gastrointest Surg (2007) 11:520–52822 (23.9%) fast proliferating and in 29 (31.5%) slowly
proliferating tumors.
Discussion
This study provides evidence of a clinically significant
biological effect of a short preoperative course of RT on
tumor proliferation rate. The impact of irradiation on
biological tumor response was assessed by BrdUrd LI,
SPF, and the degree of subsequent pathologic and clinical
down-staging of the tumors after surgery. The study
showed differences in the pretreatment proliferation rate
of the tumor. Mean BrdUrd LI before RTwas equal to 8.5%
and ranged from 1 to 24.2%. Mean SPF was 22.0%
and ranged from 3.8 to 49.9%. The proportion of cells in
S-phase as estimated by the DNA content overestimates
the labeling index determined by the uptake of BrdUrd.
This may be so because the exposure time is quite short
and there may be subpopulations in the tumors that are
synthesizing DNA at a very slow rate, or there may
indeed be cells with an S-phase DNA content that are
not synthesizing DNA (as a result of nutrient or oxygen
supply, lack of growth factors, inadequate vascularity).
Mean value of the BrdUrd LI obtained in this study was
lower than the one estimated by Bergstrom et al.
21,
Palmqvist et al.
22, and Terry et al.
23, and can be explained
by a different method used by these authors: in vivo
incorporation of iodouridine/bromodeoxyuridine, which
can cause longer exposure of the tracers to S-phase cells.
The differences in the LI value might be caused also by
heterogeneity in proliferation within the tumor. It was
shown by Bergstrom et al.
21 that rectal tumors are
polarized, having the superficial surface toward the lumen
of the gut and the other toward deep structures facing
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J Gastrointest Surg (2007) 11:520–528 525totally different environments. Apart from Bergstrom et al.,
none of the above-mentioned authors gave account of site
from where the tumor samples were taken. In each tumor
analyzed by us, all the samples were taken from the same
region, i.e., the bottom part of the mass.
In our study, pretreatment BrdUrd LI or SPF was not
predictive for early clinical and pathologicl tumor response,
probably because of different tumor microenvironment.
However, BrdUrd LI after/before RT ratio gave information
on the different significant biological processes that take
place after irradiation, and have impact on cell death like
redistribution, repopulation, and reoxygenation.
BrdUrd LI after RT decreased to mean 4.1% indepen-
dently of the time interval between RT and surgery.
Magnitude of LI reduction after RT was correlated with
tumor proliferation rate. Greater reduction of BrdUrd LI
value was observed in fast proliferating (LI >8.5%) tumors
(to mean 46% of the pretreatment value) than in slowly
(LI ≤8.5%) proliferating tumors (to mean 85.3% of
pretreatment value). What then is the justification for better
RT response of fast proliferating tumor cells? According to
current knowledge on tumor proliferation, radiation therapy
should preferentially inactivate rapidly dividing cells,
leaving behind a population biased toward slow prolifera-
tion. However, recruitment is a known effect of cytotoxic
treatment, and new cells from quiescent cell populations are
recruited into active proliferation after irradiation. Probably,
slowly proliferating tumors might have greater propensity to
recruit cells into rapid cycle in response to treatment than
fast proliferating tumors, which might have little reserve
capacity for further accelerating their cell cycle
24. That
might be why we observed acceleration of proliferation rate
in slowly proliferating tumors from 5 weeks after RT
(basing on after/before RT BrdUrd LI ratio), which
followed temporary reduction of the number of DNA-
synthesizing cells, 4–5 weeks after the start of RT.
Accelerated proliferation was confirmed by increased S-
phase fraction. However, better biological tumor respon-
siveness of fast proliferating tumors on cellular level did
not find confirmation on tissue level that is in surgery
because a fewer number of sphincter saving resections were
performed in patients with fast (22) than those with slowly
proliferating tumors (29).
Regression of rectal carcinoma after preoperative irradia-
tion varies, likely reflecting differences in the physical and
biologic properties of these tumors. Apart from biological
characteristics discussed here, tumor down-staging depends
on the total irradiation dose, the fractionation, and the interval
between irradiation and surgery
25. We showed association of
tumor proliferation rate after RT with tumor response basing
on BrdUrd LI. SPF, considered as a less sensitive method of
tumor proliferation, did not show such a correlation. The
after/before radiotherapy BrdUrd LI ratios correlated, how-
ever nonsignificantly, with the degree of pathologic and
clinical down-staging, which indicates that more radiation-
induced cell death occurred in tumors that expressed high
levels of BrUrd LI, or that an increased rate of tumor
clearance occurred in more rapidly proliferating tumors. This
effect was reflected by significantly higher incidence of
apoptosis observed after RT only in fast proliferating tumors
(4.1% vs 11.1%; P=0.000). However, patients having
tumors with LI >8.5% did not show higher rate (11.2%) of
tumor pathological down-staging (D2–D4) than patients with
BrdUrd LI ≤8.5% (16.8%) tumors, which may be suggestive
of significant impact on tumor response also by biological
processes other than proliferation. In the Spanish study
26,
high proliferative activity of rectal cancer, as determined by
PCNA immunostaining, was predictive of response to
preoperative chemoradiotherapy. Willett et al.
27, in the same
tumor type treated with higher RT dose (47–52 Gy) and
5 FU, showed that patients having tumors with extensive Ki-
67 staining had also a higher rate of tumor down-staging
(36%) 4–6 weeks after treatment than patients with minimal
to moderate Ki-67 staining tumors (22–23%). These authors
show that elevated postirradiation tumor proliferative activity
correlated strongly with improved survival
28. These authors,
in contrast to our study, did not consider the proliferation
profile of pre- and postirradiation for individual patients. The
correlation of down-staging and higher survival rates was
also found by other authors
29,30.
In our study, even in totally regressed tumors (D4), the
percentage of the after/before radiotherapy BrdUrd LI was
about 50%, which may not indicate tumor but normal cell
proliferation, mainly a fraction of activated fibroblasts or
cycling endothelial cells in capillaries high in colorectal
carcinoma
31. Our study showed complete pathologic
response (D4) similar to that in a Norwegian study (4.5%)
32,
where histological tumor slides were analyzed after
treatment with a dose of 31.5 Gy in 18 fractions and 2–
3 weeks interval between RT and surgery. However, it
should be stressed that in this study, a high incidence
(31.3%) of recurrences was observed at late follow-up. Our
analysis showed that patients having fast proliferating
tumors, as assessed by BrdUrdLI, experienced higher rates
of regression than patients with slowly proliferating tumors,
which could suggest a more frequent possibility of per-
forming sphincter-preserving procedures in these tumors.
However, this was not confirmed in surgical procedures.
Therefore, we do not know yet if pretreatment BrdUrd LI
assessment will be a good predictor for a locoregional
failure. Berger et al.
25, analyzing tumor sterilization after
preoperative RT for rectal cancer, did not find a predictive
factor for complete pathological response among such
factors as age, sex, tumor stage, and pathologic grade.
However, they found favorable influence of higher doses
(>44 Gy) on pathologic stage.
526 J Gastrointest Surg (2007) 11:520–528There is no known optimal time for the interval between
RT and surgery. The Swedish group keeps the interval at
about a week; however, in other institutions, using longer
RT treatments and higher total dose, longer intervals—4t o
6 weeks were adopted
14,25. The main reason for a longer
interval is tumor regression, which makes sphincter pre-
servation possible. Similar to Francois et al
14, we observed
higher clinical and pathologic response rate after longer
interval between RT and surgery. However, these authors
14
showed nonsignificantly better overall survival for patients
treated with shorter interval. Withers and Haustermans
33
estimated the interval between long course of fractionated
RT (40–54 Gy) and surgery and stated that the interval is
not critical to either local recurrence or distant metastases.
The authors offered the following arguments: the tumor
cells do not disseminate until the primary tumor is large
enough to be clinically detectable (probably 80% of
patients whose rectal tumors have not metastasized to
lymph nodes will be free of metastases). Irradiation with a
dose of 40 Gy in 2 Gy fractions (equivalent to 25 Gy in five
fractions) reduces tumor cell survival by about six decades,
e.g., from 10
10 to 10
4 cells. However, we have to remember
that although the short overall treatment duration in the
25 Gy in five-fraction regimen provides a radiobiological
advantage, this is a relatively low dose
34, which causes
about a 66% reduction in the rate of local recurrence
11.A
retrospective analysis of published results of preoperative
radiation therapy for rectal cancer showed that local control
probability curves were displaced toward higher doses as
the overall duration of preoperative radiation therapy was
increased
15. Therefore, longer intervals between short RT
schedule (25 Gy) and surgery may be inappropriate in case
of patients with incomplete resection (cut-through) of
primary tumor, in whom the average subclinical cancer cell
burden increases during long interval. Also, subclinical
disease beyond the future surgical margins, may be a
potential target for future recurrences. Longer intervals after
short RT can be dangerous because of potential subclinical
tumor, which may grow more quickly than primary
tumor
15,33, the and risk of developing distant metastases.
If we imply that moderately differentiated adenocarcinoma
cells have different metastatic and proliferative activities
from poorly differentiated cancer cells, which was shown
by Taniyama et al
35, then we could have an indication to
adjuvant chemotherapy for patients with differentiated
tumors. The authors
35 indicated that moderately differenti-
ated cancer cells are associated with hematogenous metas-
tases to the liver, and the loss of tubular formation of cancer
cells in poorly differentiated tumors may be fundamentally
related to lymph node metastases and infiltrative growth.
Therefore, particularly in patients with moderately differ-
entiated and slowly proliferating tumors, adjuvant chemo-
therapy could be suggested after OTT shorter than 4 weeks,
to prevent developing metastases to the liver.
In conclusion, our study shows that pretreatment BrdUrd
LI or SPF were not predictive for early clinical and
pathologic tumor response. After/before BrdUrd LI ratios
showed inhibition of proliferation in responsive tumors, but
this was not reflected in the number of sphincter preserving
procedures performed. As 1 month after RT, accelerated
proliferation of tumor cells is observed only in slowly
proliferating tumors, we think that longer interval between
RT and surgery is inadvisable.
If late tumor response confirms that patients having
tumors with increased proliferative activity have statistical-
ly significantly less recurrences and improved survival rates
compared with patients with less proliferative tumors, then
we will be able to suggest a prognostic factor for individual
rectal cancer patient, and a basis for selection to postoper-
ative adjuvant chemotherapy.
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